Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people in clinical trials used Mounjaro (tirzepatide) for 72 weeks, which is just under a year and a half. Real-world treatment duration varies more widely: some people complete a defined course and stop, others continue long-term because weight tends to return once treatment ends. Mounjaro is a prescription-only medicine; how long you should stay on it is a clinical decision your prescriber makes with you, based on your response, health goals and any comorbidities.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The pivotal SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity over 72 weeks. Participants on the highest doses lost around 20–21% of their body weight on average by the end of the study. That 72-week period is not a magic number chosen arbitrarily; it was long enough to see both the active weight-loss phase and a plateau, giving researchers a realistic picture of where the medicine levels off.
What the trial does not tell us is what happens if you stay on it for three or five years, because that data does not yet exist at scale. This is a relatively new medicine in the weight-management space, and longer-term evidence is still accumulating. Prescribers work with what the evidence currently supports, which is why the six-month review point matters so much in practice.
If you want a sense of how quickly results typically show, the pace of weight loss on Mounjaro varies considerably by dose and individual, with most people seeing meaningful change within the first four to eight weeks at a therapeutic dose.
This is the question most people quietly have but do not always ask. The honest answer, based on data from semaglutide (Wegovy) discontinuation studies and the emerging tirzepatide picture, is that weight regain is common. The biology is straightforward: Mounjaro works by activating gut-hormone receptors that suppress appetite and slow gastric emptying. Once the medicine is no longer present, those signals diminish and appetite returns toward its pre-treatment baseline.
This does not mean treatment has failed. It reflects how obesity works as a chronic condition, not a temporary one. Many clinicians now treat weight management medicines the way they treat blood-pressure medication: ongoing, not a finite course. Your prescriber will weigh this up with you based on your individual circumstances, including whether the benefits continue to outweigh any side effects. There is a separate, detailed discussion of how long you can stay on Mounjaro that covers this in full.
It is worth knowing that the cost of Mounjaro over an extended period is a real consideration for anyone self-funding privately; understanding that upfront helps people plan rather than be surprised months in.
NICE's appraisal of tirzepatide (TA1026) sets a practical checkpoint: if someone has not lost at least 5% of their body weight after six months on the highest dose they can tolerate, continuing is reviewed. That is not a punitive rule; it is a recognition that not everyone responds to the same medicine in the same way, and that continuing without evidence of benefit is not in a patient's interest.
For the majority who do respond, there is no hard upper time limit in the UK licence itself. This is where private treatment differs meaningfully from the NHS route; on the NHS, access is still phased and subject to commissioning criteria, whereas a private prescriber can continue treatment for as long as it is clinically appropriate for you. The question of how long you should stay on Mounjaro ultimately comes back to a conversation with your prescriber, reviewed regularly.
People sometimes ask whether there is a point at which the medicine simply stops working. Plateaus are normal and expected; they do not necessarily signal treatment failure. Dose titration, lifestyle factors and individual biology all play a role, and our prescribers at nume's clinical team discuss this with patients as part of every repeat review.
Going into treatment with a realistic picture of how long people typically continue is genuinely useful. It changes the financial planning, it changes the expectations around lifestyle work alongside treatment, and it changes how you interpret early results. The first pen at 2.5mg exists to help your body adjust, not to produce dramatic weight loss; the real therapeutic work builds as the dose increases over subsequent months.
Most people who find the medicine effective and tolerable end up staying on it for considerably longer than they initially expected. That is not a failure of planning; it is a reflection of how weight management actually works for many people. If you are ordering your pens, it is also worth reading about how long Mounjaro can be in transit, since understanding safe delivery windows helps you time orders sensibly and avoid gaps in treatment. For a detailed look at the first weeks, how long Mounjaro takes to work sets realistic expectations for what to look for early on.
If you are weighing up your weight-loss treatment options more broadly and wondering whether Mounjaro is the right fit, our prescribers review every consultation the same day it is submitted, a named clinician, not software. Check your eligibility by starting a free consultation with our clinical team.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.